Phenotypic changes include the enrichment of tumor-initiating cells, the histological transformation from EGFR-mutant non-small cell lung cancer to small cell lung cancer, and epithelial–mesenchymal transition resulting in therapeutic tolerance/resistance. This evidence concerns the gene EGFR and neoplasm.